

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Acotec Scientific Holdings Limited

先瑞達醫療科技控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6669)

VOLUNTARY ANNOUNCEMENT

PRC National Medical Products Administration Acceptance of Arteriovenous Access DCB Product

This announcement is made by Acotec Scientific Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that PRC National Medical Products Administration has accepted the Company’s registration application of AcoArt Orchid® & Dhalia™ for the treatment of arteriovenous fistula (AVF) stenosis on January 17, 2022.

Arteriovenous fistula (AVF) is the conduit connecting artery and vein created by surgical procedure, used for hemodialysis for patients of end-stage renal disease (ESRD). The most common complication of AV fistula is vessel stenosis caused by the change of hemodynamic caused by the fistula and the trauma caused by frequently puncture the vessel for hemodialysis. Narrowed vessel will significantly reduce the flow volume of the blood and have negative impact on the result of hemodialysis, eventually leads to the death of the patients. DCB has been proven to be effective in preventing restenosis while avoiding the complications associated with leaving a stent in the human body.

THE COMPANY MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET AcoArt Orchid® & Dhalia™ SUCCESSFULLY FOR TREATING AVF STENOSIS. SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.

By order of the Board
Acotec Scientific Holdings Limited
Jing LI
*Chairperson of the Board, Executive Director and
Chief Executive Officer*

Hong Kong, January 18, 2022

As at the date of this announcement, the executive Directors are Ms. Jing LI and Mr. Silvio Rudolf SCHAFFNER, the non-executive Directors are Mr. Ke TANG and Mr. Chen CHEN, and the independent non-executive Directors are Dr. Yuqi WANG, Ms. Hong NI and Ms. Kin Yee POON.